A study to compare the reduction in blood pressure benefits of 2 drugs Azilsartan and Cilnidipine in sugar patients.
Phase 2
Completed
- Conditions
- Health Condition 1: -
- Registration Number
- CTRI/2019/05/019168
- Lead Sponsor
- Dr SHAMEEMUNISHA
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 64
Inclusion Criteria
1.Patients with Type 2 Diabetes Mellitus > 2years duration on medical treatment with newly diagnosed Simple Hypertension (JNC8)
2.Male and Female
3.Age >40 years
4.Outpatient from Department of General Medicine.
5.BMI up to type I obesity (30-40)
6.All DM patients on OHA either single /double/triple/insulin
Exclusion Criteria
1.Renal dysfunction,
2.Patients on NSAIDS, STATIN, ASPIRIN, Immunomodulators , alternative medicines
3.Hepatic dysfunction
4.Cardiac abnormalities
5.Pregnancy and lactating women
6.Inpatients
7.ICU patients
8.EMD patients
9.Serious infections
10.PVD
11.H/o Smoking,Alcohol
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method To observe the antihypertensive benefit of Azilsartan and Cilnidipine in type 2 diabetes hypertensive patient�s cardiac and renal parameters <br/ ><br>Timepoint: PREMEDICATION PARAMETERS FBS,PPBS,hsCRP,eGFR,BP,BMI,LIPID PROFILE- WILL BE DONE 1 DAY PRIOR TO INITIATING MEDICATIO
- Secondary Outcome Measures
Name Time Method To compare Azilsartan and Cilnidipine protective effects on cardiac(hsCRP) and renal risk factors (eGFR) <br/ ><br>Timepoint: POST MEDICATION PARAMETERS FBS,PPBS,hsCRP,eGFR,BP,BMI,LIPID PROFILE- AFTER 3 MONTHS OF MEDICATION PERIOD 1 DAY LATER PARAMETERS WILL BE DONE